Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders

Seibaek, 2011, Symptom interpretation and health care seeking in ovarian cancer, BMC Womens Health, 11, 31, 10.1186/1472-6874-11-31

Bristow, 2014, High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease, Gynecol Oncol, 132, 403, 10.1016/j.ygyno.2013.12.017

Bamias, 2011, Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience, Gynecol Oncol, 123, 37, 10.1016/j.ygyno.2011.06.033

Menon, 2014, Ovarian cancer screening—current status, future directions, Gynecol Oncol, 132, 490, 10.1016/j.ygyno.2013.11.030

Poumpouridou, 2011, Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges, Clin Chem Lab Med, 50, 423

Hermsen, 2007, No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study, Br J Cancer, 96, 1335, 10.1038/sj.bjc.6603725

Hellström, 2003, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res, 63, 3695

Moore, 2008, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass, Gynecol Oncol, 108, 402, 10.1016/j.ygyno.2007.10.017

Escudero, 2011, Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases, Clin Chem, 57, 1534, 10.1373/clinchem.2010.157073

Lenhard, 2011, The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses, Clin Chem Lab Med, 49, 2081, 10.1515/CCLM.2011.709

Hertlein, 2012, Human epididymis protein 4 (HE4) in benign and malignant diseases, Clin Chem Lab Med, 50, 2181, 10.1515/cclm-2012-0097

Bast, 1998, CA125: the past and the future, Int J Biol Markers, 13, 179, 10.1177/172460089801300402

Urban, 2011, Potential role of HE4 in multimodal screening for epithelial ovarian cancer, J Natl Cancer Inst, 103, 1630, 10.1093/jnci/djr359

Schummer, 1999, Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas, Gene, 238, 375, 10.1016/S0378-1119(99)00342-X

Wang, 1999, Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray, Gene, 229, 101, 10.1016/S0378-1119(99)00035-9

Kirchhoff, 1991, A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors, Biol Reprod, 45, 350, 10.1095/biolreprod45.2.350

Bingle, 2002, The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms, Oncogene, 21, 2768, 10.1038/sj.onc.1205363

Clauss, 2002, A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein, Biochem J, 368, 233, 10.1042/bj20020869

Schalkwijk, 1999, The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core, Biochem J, 340, 569, 10.1042/bj3400569

Galgano, 2006, Comprehensive analysis of HE4 expression in normal and malignant human tissues, Mod Pathol, 19, 847, 10.1038/modpathol.3800612

Paek, 2011, Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer, Eur J Obstet Gynecol Reprod Biol, 158, 338, 10.1016/j.ejogrb.2011.05.021

Moore, 2009, A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass, Gynecol Oncol, 112, 40, 10.1016/j.ygyno.2008.08.031

Huhtinen, 2009, Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts, Br J Cancer, 100, 1315, 10.1038/sj.bjc.6605011

Nolen, 2010, Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass, Gynecol Oncol, 117, 440, 10.1016/j.ygyno.2010.02.005

Moore, 2012, Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders, Am J Obstet Gynecol, 206, e1

Anastasi, 2010, HE4: a new potential early biomarker for the recurrence of ovarian cancer, Tumour Biol, 31, 113, 10.1007/s13277-009-0015-y

Speeckaert, 2013, Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker, Adv Clin Chem, 59, 1, 10.1016/B978-0-12-405211-6.00001-2

Ferraro, 2013, Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review, J Clin Pathol, 66, 273, 10.1136/jclinpath-2012-201031

Ruggeri, 2011, HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm, Clin Chim Acta, 412, 1447, 10.1016/j.cca.2011.04.028

Jacobs, 1990, A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer, Br J Obstet Gynaecol, 97, 922, 10.1111/j.1471-0528.1990.tb02448.x

Macuks, 2012, An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions, Tumour Biol, 33, 1811, 10.1007/s13277-012-0440-1

Moore, 2010, Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass, Am J Obstet Gynecol, 203, e1

Montagnana, 2011, The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?, Clin Chem Lab Med, 49, 521, 10.1515/CCLM.2011.075

Andersen, 2010, Use of a symptom index, CA125, and HE4 to predict ovarian cancer, Gynecol Oncol, 116, 378, 10.1016/j.ygyno.2009.10.087

Van Gorp, 2012, Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses, Eur J Cancer, 48, 1649, 10.1016/j.ejca.2011.12.003

Trapé, 2011, Increased plasma concentrations of tumour markers in the absence of neoplasia, Clin Chem Lab Med, 49, 1605, 10.1515/CCLM.2011.694

Bouchard, 2006, Proteins with whey-acidic-protein motifs and cancer, Lancet Oncol, 7, 167, 10.1016/S1470-2045(06)70579-4

Lu, 2012, Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility, Biochem Biophys Res Commun, 419, 274, 10.1016/j.bbrc.2012.02.008

Li, 2013, HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines, Int J Mol Sci, 14, 6026, 10.3390/ijms14036026

LeBleu, 2013, Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis, Nat Med, 19, 227, 10.1038/nm.2989

Plebani, 2012, HE4 Study Group. HE4 in gynecological cancers: report of a European investigators and experts meeting, Clin Chem Lab Med, 50, 2127, 10.1515/cclm-2012-0373

Bignotti, 2011, Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients, Br J Cancer, 104, 1418, 10.1038/bjc.2011.109

Zanotti, 2012, Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome, Clin Chem Lab Med, 50, 2189, 10.1515/cclm-2011-0757

Kalogera, 2012, Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer, Gynecol Oncol, 124, 270, 10.1016/j.ygyno.2011.10.025

Moore, 2008, Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus, Gynecol Oncol, 110, 196, 10.1016/j.ygyno.2008.04.002

Yurkovetsky, 2010, Development of a multimarker assay for early detection of ovarian cancer, J Clin Oncol, 28, 2159, 10.1200/JCO.2008.19.2484

Bingle, 2006, WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung, Respir Res, 7, 61, 10.1186/1465-9921-7-61

Kamei, 2010, HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer, Anticancer Res, 30, 4779

Tokuishi, 2012, Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma, Tumour Biol, 33, 103, 10.1007/s13277-011-0252-8

Yamashita, 2011, Prognostic significance of HE4 expression in pulmonary adenocarcinoma, Tumour Biol, 32, 265, 10.1007/s13277-010-0118-5

Iwahori, 2012, Serum HE4 as a diagnostic and prognostic marker for lung cancer, Tumour Biol, 33, 1141, 10.1007/s13277-012-0356-9

Yamashita, 2012, Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression, Tumour Biol, 3, 2365, 10.1007/s13277-012-0499-8

Nagy, 2014, Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer, Clin Chem Lab Med, 10.1515/cclm-2014-0041

Hellström, 2010, Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms, Cancer Lett, 296, 43, 10.1016/j.canlet.2010.03.013

Macuks, 2012, Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case-control study, Asian Pac J Cancer Prev, 13, 4695, 10.7314/APJCP.2012.13.9.4695

Hellström, 2013, Anti-HE4 antibodies in infertile women and women with ovarian cancer, Gynecol Oncol, 130, 629, 10.1016/j.ygyno.2013.05.028

Hellström, 2011, Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma, Expert Opin Med Diagn, 5, 227, 10.1517/17530059.2011.559459

Bolstad, 2012, Human epididymis protein 4 reference limits and natural variation in a Nordic reference population, Tumour Biol, 33, 141, 10.1007/s13277-011-0256-4

Moore, 2012, Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age, Am J Obstet Gynecol, 206, e1

Bjerner, 2008, Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study, Scand J Clin Lab Invest, 68, 703, 10.1080/00365510802126836

Stockley, 1986, Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions, Thorax, 41, 17, 10.1136/thx.41.1.17

Anastasi, 2010, Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women, Tumour Biol, 31, 411, 10.1007/s13277-010-0049-1

Zuckerman, 1999, Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis, Am J Gastroenterol, 94, 1613, 10.1111/j.1572-0241.1999.01152.x

Liu, 2013, Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis, Int J Tuberc Lung Dis, 17, 1346, 10.5588/ijtld.13.0058

Cases, 1991, Tumor markers in chronic renal failure and hemodialysis patients, Nephron, 57, 183, 10.1159/000186247

Molina, 2002, S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function, Tumour Biol, 23, 39, 10.1159/000048687

Bruun, 2003, Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment, Nephrol Dial Transplant, 18, 598, 10.1093/ndt/18.3.598

Yilmaz, 2014, CA125 levels and left ventricular function in patients with end-stage renal disease on maintenance hemodialysis, Ren Fail, 36, 210, 10.3109/0886022X.2013.859528

Nagy, 2012, Elevated human epididymis protein 4 concentrations in chronic kidney disease, Ann Clin Biochem, 49, 377, 10.1258/acb.2011.011258

Frankel, 1996, Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure, Am J Clin Pathol, 106, 118, 10.1093/ajcp/106.1.118

Wayand, 2000, Cardiac troponin T and I in end-stage renal failure, Clin Chem, 46, 1345, 10.1093/clinchem/46.9.1345

Gerhardt, 1998, Troponin T: a sensitive and specific diagnostic and prognostic marker of myocardial damage, Clin Chim Acta, 272, 47, 10.1016/S0009-8981(97)00251-9

Maries, 2013, Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP), Cardiovasc J Afr, 24, 286, 10.5830/CVJA-2013-055

Gizzo, 2014, Could kidney glomerular filtration impairment represent the “Achilles heel” of HE4 serum marker? A possible further implication, Clin Chem Lab Med, 52, e45, 10.1515/cclm-2013-0660

Kuster, 2014, Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation, Clin Chim Acta, 428, 89, 10.1016/j.cca.2013.11.002

Su, 2013, Detection and monitoring of ovarian cancer, Clin Chim Acta, 415, 341, 10.1016/j.cca.2012.10.058

Angioli, 2014, A critical review on HE4 performance in endometrial cancer: where are we now?, Tumour Biol, 35, 881, 10.1007/s13277-013-1190-4

Melichar, 2012, Human epididymis protein 4: the start of a post-ROMAn era?, Clin Chem Lab Med, 50, 2069, 10.1515/cclm-2012-0683

Davidson, 2014, The clinical and diagnostic role of microRNAs in ovarian carcinoma, Gynecol Oncol, 133, 640, 10.1016/j.ygyno.2014.03.575